The patented ETT represents a potentially breakthrough technology in mitigating ventilator-associated pneumonia (VAP) which affects 300,000 U.S. patients annually. This ETT uniquely integrates an endotracheal tube cuff to seal the airway with a system that provides for continuous aspiration of subglottic secretions (CASS) as well as a secondary lumen that continually introduces a liquid cleansing formulation. This ETT will further reduce the incidence of harmful pathogens, including those that have become resistant to antibiotics, within the patient's respiratory system.
"This is a perfect example of growing the use of our Microcyn Technology via technologies that are not only compatible, but are significantly improved as a result of this integration," said
The endotracheal tube requires a device clearance in the United States. Oculus has entered into negotiations with two potential marketing and sales partners for this advanced technology.
"As a physician who often is involved with critically ill patients who develop ventilator associated pneumonia, I believe the incidence of ventilator-associated pneumonia can be reduced greatly by an intelligent ventilation system that adopts the multiple safeguards available in this new Oculus device," said Dr.
About Ventilator-Associated Pneumonia
Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. Intubation compromises the integrity of the oropharynx and trachea and allows oral and gastric secretions to enter the lower airways. Pneumonia is the sixth leading cause of death in
Hospital-acquired pneumonia (HAP) is pneumonia that develops 48 hours or longer after admission to a hospital. HAP is the second most common nosocomial infection. HAP increases a patient's hospital stay by approximately 7-9 days and can increase hospital costs by an average of
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "represents," "opening," and "entered," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient
settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the
Oculus and Microcyn are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. Dan McFaddenDirector of Public and Investor Relations (425) 753-2105 email@example.com
News Provided by Acquire Media